Immutep Limited is a late stage biotechnology company that focuses on the discovery and development of LAG3 related immunotherapies for cancer and autoimmune disease. The company was incorporated under the laws of the Commonwealth of Australia on May 21 1987 and originally operated as a mining business before transitioning to biotechnology in 2001 after acquiring rights from the Austin Research Institute. Following the acquisition of Immutep S A in December 2014 and a…
Immutep Limited is a late stage biotechnology company that focuses on the discovery and development of LAG3 related immunotherapies for cancer and autoimmune disease. The company was incorporated under the laws of the Commonwealth of Australia on May 21 1987 and originally operated as a mining business before transitioning to biotechnology in 2001 after acquiring rights from the Austin Research Institute. Following the acquisition of Immutep S A in December 2014 and a subsequent name change in November 2017 the firm now concentrates its efforts on a portfolio of LAG3 modulators that include the lead candidate eftilagimod alfa and several antibody programs. Its headquarters are located in Sydney Australia with additional offices in Leipzig Germany Berlin Germany and a research laboratory near Paris France. As of June 30 2025 the company employed 51 people who manage functions such as finance business development intellectual property investor relations manufacturing oversight and clinical development while relying on external contractors for trial execution and manufacturing.
Immutep Limited generates revenue mainly through licensing agreements milestone payments and royalties from partners that are developing its product candidates. The company has outlicensed the anti LAG3 antibody IMP701 to Novartis which is advancing the molecule under the name LAG525 and has received milestone payments from that partnership. Similarly the depleting antibody IMP731 was previously licensed to GSK and after the termination of that agreement the rights reverted to Immutep allowing the company to pursue further development. In addition Immutep has granted exclusive development and commercialization rights for eftilagimod alfa in China Hong Kong Macau and Taiwan to EOC Pharma in exchange for potential milestone and royalty payments. The firm also earns income from the sale of research reagents through its French subsidiary Immutep S A S which manufactures and distributes reagents to scientists via third party distributors such as Adipogen and Enzo. While no product has yet been commercialized the company anticipates future revenue from sales of its therapeutic candidates pending regulatory approval and market launch.
Immutep Limited occupies a pioneering niche in the immunotherapy sector as one of the earliest companies to explore the therapeutic potential of the LAG3 checkpoint. Its pipeline features several first in class molecules that act through distinct mechanisms including an antigen presenting cell agonist a depleting antibody an blocking antibody and an agonist antibody. This diversity allows the company to address multiple disease areas such as non small cell lung cancer metastatic breast cancer head and neck squamous cell carcinoma and autoimmune disorders without relying on a single approach. Strategic alliances with major pharmaceutical firms including Novartis GSK and Merck & Co provide external validation reduce development risk and create opportunities for milestone and royalty income. The company’s intellectual property estate comprises numerous patent families covering its key candidates and provides a barrier to entry that protects its innovations. Furthermore the leadership team possesses deep expertise in LAG3 biology which has been cultivated through years of academic collaboration and internal research giving Immutep a scientific edge over many competitors.
Immutep Limited's customers consist of pharmaceutical partners academic collaborators contract service providers and the clinical research community that conducts trials with its experimental therapies. The company’s licensing arrangements with Novartis GSK Merck & Co and EOC Pharma represent key sources of potential milestone and royalty payments and reflect confidence from established industry players. Academic collaborations such as the ongoing work with Cardiff University on small molecule LAG3 inhibitors expand the scientific foundation of the pipeline and may lead to future co development agreements. Service providers like LabCorp assist with immuno oncology research while EOC Pharma handles development of eftilagimod alfa in the Greater China region. In addition the company supplies research reagents to scientists worldwide through distributors including Adipogen and Enzo supporting basic and translational studies of LAG3 biology. Finally investigators at hospitals universities and research institutions who sponsor or participate in clinical trials constitute an important customer base for the company’s investigational products.